• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Disclosed are antitumor compounds of the formula: <IMAGE> I wherein R1 is a C2-C4 alkyl; a C3-C6 cycloalkyl; a C3-C6 cycloalkyl substituted by a halogen, hydroxy, methoxy, amino or dimethylamino group; phenyl or phenyl substituted with nitro, chlorine or methoxy; thiazyl, pyridyl, pyrazyl; or a phenyl-alkyl group of the formula X-Phe-(CH2)n-, in which X is hydrogen, halogen, hydroxyl, amino, or nitro and n is an integer from 1 to 2; R2 is hydrogen, hydroxyl or acyloxy (R-COO-), where R is an alkyl having from 1 to 11 carbon atoms; and R3 is hydrogen or trifluoroacetyl and salts thereof with pharmaceutically acceptable acids. Compounds I are prepared by condensing the aglycones thereof with 2,3,6-trideoxy-3-trifluoroacetamido-4-O-trifluoro-acetyl- alpha -L-lyxopyranosyl chloride according to a conventional technique.
    公开号:SU897111A3
    申请号:SU772541702
    申请日:1977-11-14
    公开日:1982-01-07
    发明作者:Бернарди Луиджи；Мази Паоло；Суарато Антонио；Аркамоне Федерико
    申请人:Сочиета Фармасьютичи Италия С.П.А.(Фирма)；
    IPC主号:
    专利说明:

    (5TH WAY OF OBTAINING ANTHRACYCLINE LOAN DERIVATIVES
    one
    This invention relates to a process for the preparation of new anthracycline derivatives having valuable pharmacological properties.
    The purpose of the invention is to obtain new, useful compounds, expanding it
    arsenal of means of influencing a living organism.
    This goal is achieved by synthesizing the latter, based on the well-known glycosidic synthesis reaction Koenigs-Knorr 1, according to the method of obtaining new anthracycline derivatives of the general formula
    / I. . /
    Hdi
    R. lower alkyl containing 2-4 carbon atoms, or cycloalkyl containing 3-6 carbon atoms or a phenylalkyl group of the formula
    Su
    X-Ph- (CH, j)
    X is hydrogen, halo, hydroxyl, amino or nitro; equals 1 and 2,
    n concluding that a daunomycin derivative of the general formula
    Oh he
    ,
    R, 0 O
    HE
    where R has the indicated meanings, in anhydrous dichloromethane for
    About him
    About N.YO About they he HjdO About about OdOOR But about OdOOE E / 0 About
    l about oh but
    well
    where I have the indicated values
    R4 is an alkyl group. It has been established that daunomycinone characterized by formula IV can be easily converted into its 6,7,11-trialkoxycarbonyl derivative characterized by formula V as a result of the reaction carried out at room temperature with alkyl chloroformate in the presence of a base such as
    1-2 hours at room temperature are reacted with 2,3,6-trideoxy-3-trifluoroacetamido-4-O-trifluoroacetyl-c1-b-lixopyranosyl chloride in the presence of silver trifluoromethanesulfonate followed by isolation of O, N-protected glycosides and processing them with methanol at room temperature for 2-2.5 hours in the presence of triethylamine as a catalyst, the N-trifluoroacetyl obtained protected glycosides are exposed to an aqueous solution of 0.15 N for 1-1.5 hours. NaOH to produce as a result of free glossy bases, which, in turn, are dissolved in methylene chloride and treated with 1 equivalent of hydrochloric acid in methanol.
    The target product is isolated by known techniques.
    The method of obtaining the initial compound of formula III can be represented by the following scheme
    About OSOOL "about about
    pyridine. Treatment of a compound characterized by formula V with aluminum tribromide in a suitable organic solvent (e.g. dichloromethane, chloroform, benzene) yields dimethyl analogs characterized by formula VI and which are key intermediates of the entire synthesis process. The interaction of a compound characterized by odds on QCQOR odooJif of OdOOJ 4
    58
    miula Vi, with a halide characterized by the general formula where it has the indicated banner, Y is chlorine, bro or iodine, in the presence of a base such as silver oxide, potassium carbonate, in an organic solvent and at a temperature leads to the formation of new compounds characterized. formula VII.
    The treatment is then carried out with a weak organic base, preferably a secondary amine, such as. morpholine, methylpiperazine, and the result is the formation of compounds characterized by the formula Vni, in which only the phenolic protecting group is removed. The last stage consists in weak hydrolysis with the help of a diluted inorganic base of the compound, characterized by the formula L11, into new aglycones, characterized by the formula w.
    Example 1, 4-Dimethoxy-4-ethoxydunomycin hydrochloride.
    To a solution consisting of 1.5 g of α-dimethoxy-α-etoxidunomycinone and 1.25 g of 2,3,6-tridioxy-3-trifluoroacetamido-0-trifluoroacetyl-o1-b-lyxopyranosyl chloride in 100 ml of anhydrous dichloromethane, A solution consisting of 0.95 g of silver trifluoromethanesulfonate in anhydrous diethyl ether, this solution is added dropwise with constant stirring and at room temperature. After one hour, the reaction mixture thus obtained was subjected to washing with an aqueous NaHCO solution and then evaporated to a dry product. The residue is dissolved in methanol containing 1 drop of triethylamine and then settled for 2 hours at room temperature. The solvent was removed in vacuo and the residue was subjected to chromatography (silica gel / chloroform-acetone 95/5% by volume), to obtain 0.9 g of 4-dimethoxy-α-ethoxy-M-trifluoroacetylda domycin.
    0.05 mg of 4-dimethoxy-4-ethoxy-K-trifluoroacetyldaunomycin is dissolved in 30 ml of an aqueous solution of 0.15 n. NaOH, and the resulting solution is settled for 1 hour at room temperature. After oxidation with oxalic acid and subsequent rapid neutralization with aqueous solution
    NaHCO rum and the resulting product are extracted with water and evaporated to obtain a dry product. The resulting residue is dissolved in methylene chloride and then treated with 1 equivalent of HCl in methanol. The addition of diethyl ether gives 350 mg of 4-dimethoxy-β-ethoxidunomycin hydrochloride as a precipitate, and the precipitate is collected by filtration.
    Example 2. -Dimethoxy - "- isopropyloxydanomycin hydrochloride.
    To a solution consisting of 1 g of 4-dimethoxy-isopropyl oxide-daunomicinone and 0.95 g of 2,3,6-tridioxy-3-trifluoroacetamido-0-trifluoroacetyl-eL-L-lixopyranosyl chloride in 100 ml of anhydrous dichloromethane, is added a solution consisting of 0.80 g of silver trifluoromethanesulfonate in anhydrous diethyl ether, let's take this solution is added dropwise with stirring and at room temperature. After 1 hour, the reaction mixture thus obtained was washed with an aqueous solution of NaHCO3 and evaporated to obtain a dry product. The resulting residue is dissolved in methanol containing 1 drop of three ethylamine and then left to stand at room temperature for 2 hours. The solvent is removed under vacuum, and the resulting residue is subjected to chromatography (silica gel / chloroform-acetone 95/5 ob.X) obtaining as a result 0.6 g of 4-dimethoxy-α-isopropyloxy-H-trifluoroacetyl daunomycy 1-1a. I
    权利要求:
    Claims (1)
    [1]
    0.500 g of 4-dimethoxy-α-isopropyloxy-M-trifluoroacetyldaunomycin is dissolved in 10 ml of acetone and 30 ml of aqueous 0.15 M NaOH solution and the mixture thus obtained is allowed to stand for 1 hour at room temperature. After oxidation with oxalic acid and subsequent rapid neutralization with aqueous NaHCOj, the product obtained is extracted with water and evaporated to obtain a dry product. The residue obtained is dissolved in methylene chloride and treated with an equivalent amount of HCl in methanol. As a result of the addition of diethyl ether, 0.200 g of dimethoxy-α-isopropyloxide daunomycin hydrochloride precipitate is obtained, which is collected by filtration. 7 Example 3. A-Dimethoxy-4-benzyloxydaunomycin hydrochloride. According to Example 1, from 1 g of dimethoxy-β-benzyloxydaunomicinone, 0.35 g of 4-dimethoxy-A-benzyloxy-M-trifluoroacetyl daunomycin is obtained. 0.5 g of 4-dimethoxy-β-benzyloxy-K-trifluoroacetyldaunomycin is treated with dilute NaOH of Example 1 and the result is 0.2 g of α-dimethoxy-β-benzyloxy daunomycin hydrochloride. An example. -Dimethoxy-β-cyclohexyloxy-daunomycin hydrochloride 1.2 g of 4-dimethoxy-4-cyclohexyloxy-daunomycinone is subjected to condensation with 2,3,6-tridioxy-3-fluoroacetamido-4-0-trifluoroacetyl-1-b-lyxopyranosyl chloride according to example 1, and 0.5 g dimethoxy-β-cyclohexyloxy-M-trifluoroacetyl daunomycin is obtained. According to Example 1, from 0.5 g of if-dimethoxy-cyclohexyl-N-tripto-phaceto-ethyl-daunomycin, O g, 18 g -dimethoxy-β-cyclohexyloxy-dine zinc hydrochloride is obtained. PRI me R 5 Dimethoxy-t-H-propyloxidounomycin hydrochloride. To a solution containing 1 g of di-methoxy-4-n-propyloxide-diaminicinone and 0.95 g of 2,3,6-tridioxy-3 trifluoroacetamido-O-trifluoroacetyl-ch-b-li-sopiranosyl chloride in an TOO ml of anhydrous dichloromethane, : a solution consisting of 0.8 g of silver trifluoromethanesulfonate in anhydrous diethyl ether is added dropwise with stirring at room temperature. After 1 hour, the reaction mixture thus obtained was washed with aqueous NaHC02 and evaporated to obtain a dry product. This residue is dissolved in methanol containing one drop of triethylamine and then left to stand at room temperature for 2 hours. The solvent is separated under vacuum and the resulting residue is subjected to chromatography (silica gel / chloroform-acetone in a 95/5 volume ratio) and 0.5 g of 4-dimethoxy-npropyloxy-M-trifluoroacetyldaunom- is obtained. qina. 0.5 g of dimethoxy-n-propyloxy-H-trifluoroacetyldaunomycin-18 is dissolved in 10 ml of acetone and 30 ml of water, 0.15, and the NaOH obtained as a result of which the solution is allowed to settle for 1 hour at room temperature . After oxidation with oxalic acid and neutralization with an aqueous solution of NaHCOi, the product obtained is extracted with water, and the aqueous solution is evaporated under vacuum to obtain a residue of dry product. This dry product is further subjected to dissolution in methylene chloride and treated with 1 equivalent of HCl in methanol. As a result of the addition of diethyl ether, 0.18 g of dimethoxy-4-n-propyloxidownomycin hydrotchloride is obtained in the form of a precipitate which is collected by filtration. Thin layer chromatography (TLC) on silica gel plates F i254 Smerk) - chloroform / methanol / water solvent system 130/60/10, 25. PRI me R 6. 4-Dimethoxy-4-n: -butyloxy-oxidomycin hydrochloride. 1.5 g of 4-dimethoxy-4-n-butyloxy-oxidomycinone is reacted with 1.5 g of b-tridioxy-3-trifluoroacetamido -O-trifluoroacetyl-cL-N-lixopyranosyl chloride in anhydrous dichloromethane and in the presence of 1.2 g silver trifluoromethanesulfonate according to example 1. As a result, 0.90 g of 4-dimethoxy-n-butyloxy-N-trifluoroacetyl daunomycin is obtained. Thin-layer chromatography (TLC) on silica gel plates F 254 (Merck) - chloroform / methanol / water solvent system 130/60/10 R 0.5. 0.8 g of 4-dimethoxy-} n-butyloxy-M-trifluoroacetyldaunomycin is subjected to hydrolysis with an aqueous 0.15 M solution of NaOH in example 1, to obtain 0.3 g -dimethoxy- (-butyloxy-oxidomycin hydrochloride. Example 7. "-Dimethoxy - -second-butyloxy-oxidomycin hydrochloride. 0.4 g of 4-dimethoxy-4-sec-butyloxy-oxidomycinone is treated with 0.39 g of 2,3,6-tridioxy-3-trifluoroacetamido-4-0-trifluoroacetyl-c1-Cglyxopyranosyl chloride in the presence of 0.3 g of silver trifluoromethanesulfonate of Example 1 and as a result, 0.2 g of d-dimethoxy-β-second 9-butyloxy-trifluoroacetyldaunomycy are obtained on 0.15 g + -dimethoxy - + - sec-butyl hydroxy-H-trifluoroacetyldaunomycin under treatment with aqueous 0.15 M NaOH solution of example 1, as a result, 0.05 g of dimethoxy-second-byvyl-hydroxyideminicin hydrochloride is obtained Example 4. 4-Dimethoxy - + - from butyloxidunomycin hydrochloride; 0.7 g-dimethoxy - + - isobutyloxy daunomycinone is treated with 0.63 g of 2,3,6-tridioxy-3-trifluoropace amido- -0-trifetropacetil-aL-L-likospi jlorosylchloride in the presence of 0.5 g of silver trifluoromethanesulfonate as in example 1 and as a result 0.3 g of + -dimethoxy-isobutyloxy-M-trifluoroacetyldaunomycin is obtained. 0.25 g of dimethoxy - + - isobutyloxy-N-trifluoroacetyldauAomycin is subjected to treatment with aqueous 0.15 M NaO solution of example 1 and as a result 0.08 g of A-dimethoxy - + - isobutyloxy | daunomycin hydrochloride is obtained. Thin-layer chromatography (TLC) on silica gel plates F 25 (Merck) - solvent system chloroform / methanol / water 130/60/10 R 0.5. The invention of the method for producing anthracycline derivatives of general formula IO he II -ti-dH. 1110 where R is a lower alkyl containing 2-k carbon atoms, or cycloalkyl containing 3-6 carbon atoms, or a phenylalkyl group characterized by the formula i X - Ph - (CH) „where X is hydrogen, halo, hydroxyl, amino or nitro group; n is 1 or 2, characterized in that the daunomycin derivative of the formula 1and R, 0 O where R has the indicated values, in anhydrous dichloromethane for 1-2 hours at room temperature, is reacted with 2,3,6-1-ridioxy-3- trifluoroacetamido-4-0-trifluoroacetyl-d. L-lixopyranosyl chloride in the presence of silver trifluoromethanesulfonate followed by isolation of O, N-protected glycosides and their treatment with methanol at room temperature for 2-2.5 h in the presence of triethylamine as a catalyst, N-trifluoroacetyl obtained glycosides for 1-1, 5 h is subjected to contact with an aqueous solution of 0.15 n. NaOH to produce free glycosidic bases, which are then dissolved in methylene chloride and treated with 1 equivalent of hydrochloric acid in methanol. Sources of information, spirited into account during the examination 1. Kochetkov N.K., Bochkov A.F., Dmitriev B.A., Usov A.I., Chizhov O.S., Shibaev V.N. Chemistry of carbohydrates. M., 1967, c.E.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU897111A3|1982-01-07|Method of preparing anthracycline derivatives
    CA1099705A|1981-04-21|Process for the preparation of new daunomycin derivatives and their aglycones
    SU1729294A3|1992-04-23|Method for preparation 4-demethoxy-7-deoxy-daunomycinone or 4-demetoxy-daunomycinone
    SU993822A3|1983-01-30|Process for producing antracycline glycosides
    Yi et al.2014|Synthesis of 4, 5-disubstituted-3-deoxy-d-manno-octulosonic acid | derivatives
    US4188377A|1980-02-12|Carminomycin derivatives, their preparation and use
    US4973674A|1990-11-27|Chiral synthesis of anthracyclines from substituted anthraquinones
    RU2320653C2|2008-03-27|6r-|heptanoic acid for treatment of diseases associated with aging and stress and method for its preparing
    JP6923520B2|2021-08-18|Novel 5-azido-5-deoxy-2: 3-isopropylidene-D-arabinose compounds, methods of their preparation, and their use for the synthesis of Ara-N3, Kdo-N3 and 4eKdo-N3.
    SU1017173A3|1983-05-07|Process for preparing anthracycline glycosides
    SU1590045A3|1990-08-30|Method of producing glycoside
    DK165790B|1993-01-18|PROCEDURE FOR PREPARING ADRIAMYCIN-4&#39;-O DERIVATIVES OR ACID ADDITION SALTS THEREOF
    US4191755A|1980-03-04|Novel daunomycin derivatives, their aglycones and the use thereof
    JPH0660191B2|1994-08-10|Novel anthracycline lycosides, method for producing them, and antitumor agent containing them
    EP0081305B1|1985-04-24|Erythromycin a derivatives
    SU867315A3|1981-09-23|Method of preparing substituted anthracycline chlorohydrates
    SU1429935A3|1988-10-07|Method of producing 6 - deoxyanthracyclineglycosides
    RU2071463C1|1997-01-10|Process for preparing 4-substituted anthracyclinones
    RU2073681C1|1997-02-20|Anthracycline glycoside and method of its synthesis
    SU650507A3|1979-02-28|Method of obtaining glycoside antibiotics or their hydrochlorides
    RU2077526C1|1997-04-20|Method for production of anthracyclones
    Kuzuhara et al.1975|Stereoselective synthesis of 5-O-carbamoylpolyoxamic acid (2-amino-5-O-carbamoyl-2-deoxy-l-xylonic acid
    RU2095365C1|1997-11-10|8-fluoroanthracycline glycosides or pharmaceutically acceptable acid addition salts thereof, method of preparation thereof, pharmaceutical composition, intermediate compounds, and method of preparation thereof
    US20060100421A1|2006-05-11|Compositions and processes for preparing 13-deoxy-anthracyclines
    US4134903A|1979-01-16|Anthracycline ethers and their preparation
    同族专利:
    公开号 | 公开日
    AT356268B|1980-04-25|
    AU3057977A|1979-05-17|
    DE2750812A1|1978-05-18|
    FI773433A|1978-05-17|
    DK148059B|1985-02-18|
    US4327029A|1982-04-27|
    FI63590B|1983-03-31|
    HU177041B|1981-06-28|
    ATA806877A|1979-09-15|
    US4166848A|1979-09-04|
    BE860782A|1978-03-01|
    CA1090787A|1980-12-02|
    SE435387B|1984-09-24|
    ZA776812B|1978-09-27|
    IE46165B1|1983-03-09|
    AU519681B2|1981-12-17|
    NZ185677A|1979-06-19|
    YU269977A|1982-08-31|
    NO145762B|1982-02-15|
    GB1567456A|1980-05-14|
    DE2750812C2|1986-01-09|
    CS221274B2|1983-04-29|
    FR2370754A1|1978-06-09|
    DK502977A|1978-05-17|
    DK148059C|1985-07-29|
    IL53378A|1981-12-31|
    FR2370754B1|1982-10-22|
    NL7712390A|1978-05-18|
    PH14874A|1982-01-08|
    NO773892L|1978-05-18|
    GR71885B|1983-08-04|
    FI63590C|1983-07-11|
    CH634336A5|1983-01-31|
    JPS5363366A|1978-06-06|
    IL53378D0|1978-01-31|
    IE46165L|1978-05-16|
    SE7712861L|1978-05-17|
    JPS6133037B2|1986-07-31|
    NO145762C|1982-05-26|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3074975A|1960-11-07|1963-01-22|American Cyanamid Co|Naphthacenequinones|
    US3201424A|1962-10-29|1965-08-17|American Cyanamid Co|Derivatives of 1, 3, 11, 12-tetrahydroxynaphthacene and 1, 3, 6, 11-tetrahydroxynaphtacene-5, 12-quinone|
    US3803124A|1968-04-12|1974-04-09|Farmaceutici It Soc|Process for the preparation of adriamycin and adriamycinone and adriamycin derivatives|
    GB1511559A|1975-09-26|1978-05-24|Farmaceutici Italia|Anthracycline glycosides|
    GB1509875A|1976-06-14|1978-05-04|Farmaceutici Italia|Optically active anthracyclinones and anthracycline glycosides|US4316985A|1979-01-16|1982-02-23|Hoffmann-La Roche Inc.|Cyclic compounds|
    US4299822A|1980-06-09|1981-11-10|Sidney Farber Cancer Institute, Inc.|N-Trifluoroacetyladriamycin-14-O-hemiglutarate and -hemiadipate and therapeutic compositions containing same|
    US4413120A|1981-04-06|1983-11-01|Purdue Research Foundation|Process for producing acosamine, daunosamine, 1-thioacosamine and related compounds|
    US4870058A|1982-12-20|1989-09-26|Ohio State University Research Foundation|14-Acyloxy-2'-halo-anthracycline anti-cancer antibiotics|
    GB8317037D0|1983-06-23|1983-07-27|Erba Farmitalia|6-deoxyanthracyclines|
    JPS61501388A|1983-10-19|1986-07-10|
    US4537882A|1984-05-10|1985-08-27|Ohio State University|4-Demethoxy-3'-desamino-2'-halo-anthracycline and pharmaceutical composition containing same|
    GB8426672D0|1984-10-22|1984-11-28|Erba Farmitalia|Pharmaceutical compositions|
    JPS63106741A|1986-10-24|1988-05-11|Asahi Optical Co Ltd|Color separation optical reader|
    NZ224252A|1987-04-21|1991-09-25|Erba Carlo Spa|An anthracycline glycoside and its preparation|
    WO1989006654A1|1988-01-19|1989-07-27|Board Of Regents, The University Of Texas System|Glycosides, liposomal compositions thereof, and methods for their use|
    GB9216962D0|1992-08-11|1992-09-23|Erba Carlo Spa|Therapeutically active naphthalenesulfonic-pyrrolecarboxamido derivatives|
    AU6364094A|1993-03-12|1994-09-26|Board Of Regents, The University Of Texas System|Anthracyclines with unusually high activity against cells resistant to doxorubicin and its analogs|
    GB9416007D0|1994-08-08|1994-09-28|Erba Carlo Spa|Anthracyclinone derivatives|
    GB9418260D0|1994-09-09|1994-10-26|Erba Carlo Spa|Anthracycline derivatives|
    DE102004010219B4|2004-02-27|2007-02-01|Hans-Knöll-Institut für Naturstoff-Forschung e.V.|HKI10311129, new antibiotic, process for its preparation and pharmaceutical compositions containing HKI10311129|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    GB47601/76A|GB1567456A|1976-11-16|1976-11-16|Daunomycin derivatives|
    [返回顶部]